Home / Health / AstraZeneca India Gets Green Light for New Cancer Treatment
AstraZeneca India Gets Green Light for New Cancer Treatment
31 Jan
Summary
- CDSCO approved AstraZeneca Pharma India's Imfinzi solution.
- The treatment targets adult patients with resectable gastric cancer.
- Approval allows import, sales, and distribution for a new indication.
AstraZeneca Pharma India announced on January 31, 2026, that it has secured approval from the Central Drugs Standard Control Organisation (CDSCO). This approval pertains to Imfinzi, also known as durvalumab solution, for a new therapeutic use.
The newly approved indication is for adult patients diagnosed with resectable gastric or gastroesophageal junction adenocarcinoma. This marks a significant advancement in targeted cancer therapies available within India.
The CDSCO's permission specifically covers the import, sales, and distribution of Imfinzi in solution for infusion, in strengths of 120 mg/2.4 ml and 500 mg/10 ml. This allows for its use in conjunction with FLOT chemotherapy as neoadjuvant and adjuvant treatment, followed by single-agent durvalumab.
This regulatory milestone paves the way for the broader marketing of Imfinzi in India for this specific cancer indication, pending any further statutory approvals. AstraZeneca Pharma India's shares saw a 1.8% increase in the previous trading session.
